218 related articles for article (PubMed ID: 22814886)
1. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
[TBL] [Abstract][Full Text] [Related]
2. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
3. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
4. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
6. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study.
Gacci M; Cai T; Siena G; Minervini A; Torshizi MF; Bartolini M; Giannì G; Saieva C; Ceroti M; Detti B; Livi L; Pupi A; Carini M
Scand J Urol; 2014 Jun; 48(3):259-67. PubMed ID: 24255954
[TBL] [Abstract][Full Text] [Related]
9. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
[TBL] [Abstract][Full Text] [Related]
10. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
11. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
Breeuwsma AJ; Pruim J; van den Bergh AC; Leliveld AM; Nijman RJ; Dierckx RA; de Jong IJ
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):160-4. PubMed ID: 19783375
[TBL] [Abstract][Full Text] [Related]
12. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
[TBL] [Abstract][Full Text] [Related]
13.
Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
[TBL] [Abstract][Full Text] [Related]
14.
Garg I; Nathan MA; Packard AT; Kwon ED; Larson NB; Lowe V; Davis BJ; Haloi R; Mahon ML; Goenka AH
J Cancer Res Ther; 2021; 17(2):358-365. PubMed ID: 33063697
[TBL] [Abstract][Full Text] [Related]
15. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
16. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
17. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
Rinnab L; Mottaghy FM; Blumstein NM; Reske SN; Hautmann RE; Hohl K; Möller P; Wiegel T; Kuefer R; Gschwend JE
BJU Int; 2007 Oct; 100(4):786-93. PubMed ID: 17822459
[TBL] [Abstract][Full Text] [Related]
19. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
Breeuwsma AJ; Rybalov M; Leliveld AM; Pruim J; de Jong IJ
Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
[TBL] [Abstract][Full Text] [Related]
20. Value of
García JR; Compte A; Buxeda M; Mourelo S; Soler M; Blanch A; Valls E; Riera E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):197-203. PubMed ID: 32165153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
